Typefaces

SF New Deal is Distributing $1,000,000 to Small Businesses for Debt Relief

Retrieved on: 
Tuesday, June 1, 2021

In order to support small businesses and strengthen local communities, SF New Deal is providing grants of $2,500 to 400 small businesses.

Key Points: 
  • In order to support small businesses and strengthen local communities, SF New Deal is providing grants of $2,500 to 400 small businesses.
  • A March 2021 SF New Deal survey of San Francisco restaurants found that the number of restaurants facing debt, as well as the amount of debt, has increased significantly.
  • SF New Deals grant program is open to all small businesses, including newly opened businesses, that have not previously participated in any of SF New Deals programs.
  • Application and nomination details are listed on the SF New Deal Small Business Debt Relief Grant Program Page .

EQS-News: Capital increase of HSL Fund significantly oversubscribed

Retrieved on: 
Friday, May 28, 2021

Zurich, 28 May 2021 - The capital increase of the residential real estate fund Helvetica Swiss Living Fund (HSL Fund) was completed successfully.

Key Points: 
  • Zurich, 28 May 2021 - The capital increase of the residential real estate fund Helvetica Swiss Living Fund (HSL Fund) was completed successfully.
  • Helvetica Property Investors AG is a leading real estate fund management company and asset management firm.
  • The HSL Fund is a Swiss real estate fund open exclusively to qualified investors.
  • The HSL Fund invests in residential real estate throughout Switzerland, primarily where regional and national economic centers are easily accessible.

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

Retrieved on: 
Monday, May 24, 2021

SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA.

Key Points: 
  • SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA.
  • Q2 Solutions provides comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions.
  • Myriad RBM, which specializes in contract research services for the pharmaceutical industry, will be added to the overall Q2 Solutions menu and offerings.
  • Our agreement with Q2 Solutions provides a good home for Myriad RBM teammates, delivers strong value, and provides significant capital for future growth, said Paul J. Diaz, president and CEO of Myriad Genetics.

Lydian Academy Announces Appointment of New Principal in Burlingame, CA

Retrieved on: 
Friday, May 21, 2021

b'MENLO PARK, Calif., May 21, 2021 /PRNewswire-PRWeb/ -- Lydian Academy is pleased to welcome Christiana Cassio, a skilled leader and pioneer in one-to-one education, as Principal of the newly opening Lydian Academy campus in Burlingame.\nMrs.

Key Points: 
  • b'MENLO PARK, Calif., May 21, 2021 /PRNewswire-PRWeb/ -- Lydian Academy is pleased to welcome Christiana Cassio, a skilled leader and pioneer in one-to-one education, as Principal of the newly opening Lydian Academy campus in Burlingame.\nMrs.
  • With a track record of effective school leadership, she brings extensive experience and insightful perspectives to Lydian.
  • I\'m so happy to see that the core values of Lydian are thriving under the next generation of leaders.
  • "\nFounded in 2006, Lydian Academy is a personalized middle and high school focused on college preparatory education and fully accredited by the Western Association of Schools and Colleges (WASC).

OraSure Technologies Appoints Scott Gleason As Senior Vice President Investor Relations and Corporate Communications

Retrieved on: 
Monday, May 17, 2021

b"BETHLEHEM, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Scott Gleason has been appointed Senior Vice President Investor Relations and Corporate Communications effective today.\nPrior to joining OraSure, Mr. Gleason served as the Senior Vice President of Investor Relations and Corporate Strategy for Myriad Genetics, Inc., a leading specialty diagnostic laboratory in the United States focused on genetic testing and precision medicine.

Key Points: 
  • b"BETHLEHEM, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Scott Gleason has been appointed Senior Vice President Investor Relations and Corporate Communications effective today.\nPrior to joining OraSure, Mr. Gleason served as the Senior Vice President of Investor Relations and Corporate Strategy for Myriad Genetics, Inc., a leading specialty diagnostic laboratory in the United States focused on genetic testing and precision medicine.
  • At Myriad, he managed the investor relations and corporate communications functions, led the annual strategic planning process, and was a member of the Company's strategic committee.
  • Before joining Stephens, Inc. Mr. Gleason was a United States Air Force aircraft maintenance officer and participated in two wartime deployments.
  • Mr. Gleason received a Bachelor of Science degree from the U.S. Air Force Academy in Colorado Springs, CO.\n\xe2\x80\x9cWe are delighted to welcome Scott as the Company\xe2\x80\x99s new Senior Vice President Investor Relations and Corporate Communications.

FUTURA Jewelry Launches the First Mercury-Free Gold Jewelry Collection to Reduce the Global Threat of Mercury Emissions to Our Planet

Retrieved on: 
Thursday, May 13, 2021

Each piece of FUTURA Jewelry reduces harmful mercury emissions from our planet, and ensures a safer and healthier tomorrow.

Key Points: 
  • Each piece of FUTURA Jewelry reduces harmful mercury emissions from our planet, and ensures a safer and healthier tomorrow.
  • Our gold is setting the standard for the future - for the jewelry industry and for the planet.
  • FUTURA collaborates with world renowned jewelry historians from iconic cultural centers to discover history\'s most imaginative jewelry designs that have a modern relevance.
  • Responsible and compassionate luxury jewelry is the ethos of FUTURA.\nTo find out additional information and to discover the full FUTURA collection, please visit\n'

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

Retrieved on: 
Monday, May 3, 2021

b'SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra\xc2\xae test, from Myriad Autoimmune\xe2\x80\x99s business unit to Labcorp (NYSE: LH) for $150 million in cash.

Key Points: 
  • b'SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property (IP), including the Vectra\xc2\xae test, from Myriad Autoimmune\xe2\x80\x99s business unit to Labcorp (NYSE: LH) for $150 million in cash.
  • Labcorp is a leading global life sciences company and one of the nation\xe2\x80\x99s largest laboratory service providers.\n\xe2\x80\x9cOur agreement with Labcorp meets our goals of ensuring broad access to the Vectra\xc2\xae test for patients, ensuring a good home for our teammates, and delivering strong value for our shareholders,\xe2\x80\x9d said Paul J. Diaz, president and CEO of Myriad Genetics.
  • Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs.
  • For more information on how Myriad fulfills its purpose, please visit the Company\'s website: www.myriad.com .\nMyriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Umbra Raises $32M to Expand Satellite Constellation

Retrieved on: 
Wednesday, April 28, 2021

b'SANTA BARBARA, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Umbra, a 5.5-year-old Santa Barbara-based intelligence and technology company, announced that it has raised $32 million in equity financing.

Key Points: 
  • b'SANTA BARBARA, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Umbra, a 5.5-year-old Santa Barbara-based intelligence and technology company, announced that it has raised $32 million in equity financing.
  • Umbra has agreements to deliver data to the United States government and commercial geospatial intelligence (GEOINT) firms.\nUmbra was founded with a contract from a prime aerospace and defense firm.
  • "When we embarked on the commercial business it was clear Umbra needed to invent something new to create value for our customers."
  • said Gabe Dominocielo, Umbra\'s co-founder.\nRecently, Umbra was granted a patent for its deployable antenna, which allows the company to launch multiple satellites on a SpaceX rideshare.

OCON's Pioneering IUB™ Ballerine® Femtech Applauded by Frost & Sullivan

Retrieved on: 
Friday, April 23, 2021

Its safety, quality, and comfort advantages have already earned it a global customer base," said Suchismita Das, Industry Analyst.

Key Points: 
  • Its safety, quality, and comfort advantages have already earned it a global customer base," said Suchismita Das, Industry Analyst.
  • "\nUnderstanding the myriad of issues women face with rigid T-shaped IUDs, OCON created the IUB Ballerine to be uniquely spherical and small (15 mm in diameter).
  • Its exceptional properties have increased its acceptance rates among women of different age groups and position the company for continued domination of the femtech space.
  • "\nEach year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of new products and applications.

OCON's Pioneering IUB™ Ballerine® Femtech Applauded by Frost & Sullivan

Retrieved on: 
Friday, April 23, 2021

Its safety, quality, and comfort advantages have already earned it a global customer base," said Suchismita Das, Industry Analyst.

Key Points: 
  • Its safety, quality, and comfort advantages have already earned it a global customer base," said Suchismita Das, Industry Analyst.
  • "\nUnderstanding the myriad of issues women face with rigid T-shaped IUDs, OCON created the IUB Ballerine to be uniquely spherical and small (15 mm in diameter).
  • Its exceptional properties have increased its acceptance rates among women of different age groups and position the company for continued domination of the femtech space.
  • "\nEach year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of new products and applications.